UBS Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

UBS Group’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,020	Closed	-$144K	–	11000
2021 Q3	$144K	Buy	+1,020	New	+$202K	﹤0.01%	5569

Other funds holding EVLO

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group's EVLO Position: Q4 2023 in Review

UBS Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 923 shares — an estimated $3.62K sold.

UBS Group first reported a position in EVLO in Q2 2018 and held it in 20 quarters. The position peaked at $85K in Q4 2018. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

UBS Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
UBS Group sold 923 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $3.62K.
UBS Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 20 quarters.
UBS Group's Evelo Biosciences, Inc. Common Stock position peaked at $85K in Q4 2018.
2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.